NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · DRMA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Dermata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Dermata Therapeutics, Inc.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of -$0.55. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dermata Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 17, 2025 |
| -$13.40+10.67% vs estimate |
| $0.00 |
| Q3 2024 | Nov 13, 2024 | -$20.40+22.73% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$2.31-$0.02 (-0.86%)
Artelo Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.71% below the high.
$5.60+$0.09 (+1.63%)
GT Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.52% below the high.
$2.64+$0.07 (+2.72%)
PMGC Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
$3.75+$0.03 (+0.81%)
Revelation Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.76% below the high.
$1.32+$0.12 (+10.0%)
Virax Biolabs Group Limited’s quoted price sits in the lower half of its reported 52-week range, 93.93% below the high.
$0.38$0.00 (0.0%)
Avenue Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.8% below the high.
$3.61+$0.21 (+6.18%)
Psyence Biomedical Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.2% below the high.
